Oracle Completes Acquisition of Phase Forward
The Webex conference for customers and partners this morning allowed Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences, to provide Oracle's overarching strategy in regard to IT in all vertical markets. He then drilled down into its strategy for the Health Sciences unit, which is based on the ultimate convergence of life sciences and healthcare processes into translational and personalized medicine--and specifically using the efficiencies of data interoperability as necessary to achieve the goals.
From Phase Forward's perspective, both Steve Rosenberg, Senior Vice President, Products and Services, and Steve Powell, Senior Vice President Global Sales and Marketing, presented the benefits of the merger for customers. The main takeaway from Rosenberg for Phase Forward customers was that their "investment protected and their services intact."
In the new structure, customers will be able to take advantage of Oracle's Applications Unlimited, which offers customers basically whatever they choose moving forward..stay on the existing platform, upgrade or update to others, etc.
Powell reiterated that the merger was transformational in the industry and that by choosing Phase Forward, Oracle emphasizes the need of its applications within this industry, which will command a significant level of investment in the coming years.
Powell said that all upcoming Oracle and Phase Forward events this year are unaffected by the purchase. These events include Oracle's
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025